WHO claims landmark agreement to improve global preparedness for flu pandemics

18 April 2011

The World Health Organization announced yesterday that, after a week of negotiations continued through Friday night and into Saturday morning, an open-ended working-group meeting of member states successfully agreed upon a Framework that ensures that, in a pandemic, influenza virus samples will be shared with partners who need the information to take steps to protect public health.

The working-group meeting was convened under the authority of the World Health Assembly and coordinated by the WHO, and will be presented to the Assembly meeting in taking place in May for consideration and approval. The negotiations started four years ago, after the emergence of the bird flu virus epidemic in Southeast Asia.

The new Framework includes certain binding legal regimes for the WHO, national influenza laboratories around the world and industry partners in both developed and developing countries that will strengthen how the world responds more effectively with the next flu pandemic. By making sure that the roles and obligations among key players are better established than in the past - including through the use of contracts - the Framework will help increase and expedite access to essential vaccines, antivirals and diagnostic kits, especially for lower-income countries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical